Wed, 22nd Jul 2015 06:27
LONDON, July 22 (Reuters) - AstraZeneca's muchanticipated cancer drug pipeline suffered a blow on Wednesdaywhen the experimental drug selumetinib failed to meet its goalin a late-stage trial for uveal melanoma.
The drugmaker said the setback would not affect otherstudies using the drug. Selumetinib is being investigatedprimarily as a treatment for advanced non-small cell lungcancer. (Reporting by Ben Hirschler, editing; by Louise Heavens)
(Correcting company name in headline)
(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsort...
(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out...
(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for pr...
(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood canc...
Astrazeneca (AZN)